Navigation Links
Galmed Pharmaceuticals Second Quarter 2014 Conference Call and Webcast Scheduled for Friday, July 25, 2014
Date:7/21/2014

TEL AVIV, Israel, July 21, 2014 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed"), a clinical-stage biopharmaceutical company focused on the development and commercialization of a once-daily, oral therapy for the treatment of liver diseases and cholesterol gallstones, announced today that it will host a conference call and webcast on Friday, July 25, 2014 to discuss results for the period ended June 30, 2014 and to provide an update on current developments with respect to its clinical program for aramchol.

Conference Call & Webcast
Friday, July 25, 2014, 8:30am Eastern Time/5:30am Pacific Time

Domestic:                                888-299-7209
International:                            719-325-2376
Webcast                                  http://galmedpharma.investorroom.com/events-and-presentations

Replay, available until August 9, 2014

Domestic:                                877-870-5176
International:                            858-384-5517
Passcode                                9373657.

About Galmed Pharmaceuticals Ltd.
Galmed is a clinical-stage biopharmaceutical company focused on the development and commercialization of a novel, once-daily, oral therapy for the treatment of liver diseases and cholesterol gallstones utilizing its proprietary first-in-class family of synthetic fatty-acid/bile-acid conjugates, or FABACs. Galmed believes that its product candidate, aramchol, has the potential to be a disease modifying treatment for fatty liver disorders, including Non-Alcoholic Steato-Hepatitis, or NASH, which is a chronic disease that Galmed believes constitutes a large unmet medical need.

Cautionary Note on Forward-Looking Statements
This press release includes forward-looking statements. Such forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such statements. Applicable risks and uncertainties include those identified under the heading "Risk Factors" included in the registration statement on Form F-1 (File No. 333 -193792), initially filed with the Securities and Exchange Commission, or the SEC, on February 6, 2014 and declared effective by the SEC on March 12, 2014, and in other filings that Galmed has made and may make with the SEC in the future. The forward-looking statements contained in this press release reflect Galmed's current views with respect to future events, and Galmed does not undertake and specifically disclaims any obligation to update any forward-looking statements.


'/>"/>
SOURCE Galmed Pharmaceuticals Ltd.
Copyright©2014 PR Newswire.
All rights reserved

Related medicine technology :

1. Savient Pharmaceuticals to Hold First Quarter 2012 Financial Results Conference Call on Wednesday, May 9, 2012
2. Auxilium Pharmaceuticals to Present at the Deutsche Bank 37th Annual Healthcare Conference
3. Nouveau Life Pharmaceuticals (HRID) Contracts with U.S. Manufacturer to Produce New Female Supplement
4. BioElectronics Survey Indicates a Five-Fold Superior Pain Relief Compared to OTC Pharmaceuticals
5. Icahn Issues Statement Regarding Amylin Pharmaceuticals
6. Almost 50 Percent of the Glaucoma Patient Population Remains Untreated, Signifying a Vast Market for Glaucoma Pharmaceuticals, Finds Frost & Sullivan
7. Omthera Pharmaceuticals Announces Positive Top-Line Results from Phase 3 EVOLVE Study
8. Onyx Pharmaceuticals Announces FDA Advisory Committee to Review Carfilzomib for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma
9. Jazz Pharmaceuticals Announces First Quarter 2012 Financial Results Conference Call On May 8, 2012
10. Inovio Pharmaceuticals Granted U.S. Patent Protection for Synthetic Vaccine for Cervical Dysplasia and Cancer
11. Avanir Pharmaceuticals To Present at Three Conferences In May
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2017)... 20, 2017 Research and Markets has ... Manufacturing Services Market Analysis By Service (Manufacturing, Research), By Country, ... - 2025" report to their offering. ... The Latin American pharmaceutical contract manufacturing ... 2025 Low drug registration cost in Latin American ...
(Date:4/19/2017)... 2017 Global Surgical Drainage Device Market: Overview ... to remove excess liquid and air. The fluid to ... or lymph. Surgical drains are used in a wide ... surgery, cardiovascular surgery, neurosurgery, plastic surgery etc. Common use ... accumulation of fluid e.g. blood or pus. Surgical drains ...
(Date:4/19/2017)... , April 19, 2017 ... an immune response in pets such as canine, ... are of various types such as Attenuated Live ... Vaccines, DNA Vaccines and Recombinant Vaccines. Attenuated live ... virus or bacteria, which have been weakend under ...
Breaking Medicine Technology:
(Date:4/26/2017)... Aviv, Israel (PRWEB) , ... April 26, 2017 , ... ... today announced a new partnership with Med-e-Mass , the largest Electronic Medical Records ... enable Med-e-Mass to link care plan incentives to a patient’s remote health progress, empowering ...
(Date:4/26/2017)... ... April 26, 2017 , ... Infertility may be a result ... has helped many women become pregnant upon treating their diagnosis. , ... outpatient evaluations. We can provide the necessary information to diagnose and treat ...
(Date:4/26/2017)... ... April 26, 2017 , ... Want to ... website ( CRISPRCas.pioneer.com ) that demonstrates how this advanced plant breeding technology is ... better food, with fewer resources. It highlights the business’ principles, research and collaboration ...
(Date:4/26/2017)... (PRWEB) , ... April 26, 2017 , ... ... human performance, is proud to announce that it has received 510(k) clearance from ... the MyoCycle Home and the MyoCycle Pro. , Both devices are stationary cycling ...
(Date:4/25/2017)... ... April 25, 2017 , ... ProRehab Physical ... be the preferred physical therapy provider for Derby City CrossFit, effective immediately. , ... CrossFit as quickly and effectively as possible, ProRehab’s sports physical therapists will work ...
Breaking Medicine News(10 mins):